Related Experiment Video
Updated: Aug 12, 2026
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
CD101 expression by Langerhans cell histiocytosis cells
A Bouloc1, M L Boulland, F Geissmann
1Department of Dermatology; INSERM U448; Department of Pathology, Hôpital Henri-Mondor, Créteil, France. bouloc@univ-paris12.fr
Insights
CD101 expression may aid in diagnosing Langerhans cell histiocytosis (LCH). While useful with other markers, its application is limited to frozen sections, unlike CD1a. Further research is needed.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Langerhans cell histiocytosis (LCH) is a rare disorder characterized by the abnormal proliferation of Langerhans cells.
- CD101 is a cell surface molecule expressed on dendritic cells, including Langerhans cells.
Purpose of the Study:
- To investigate CD101 expression in LCH patients.
- To evaluate CD101 as a diagnostic marker for LCH, potentially in conjunction with CD1a and S100 protein.
- To assess if CD101 expression predicts disease evolution and dissemination.
Main Methods:
- Immunohistochemical analysis of CD101 expression was performed on frozen tissue sections from 11 LCH cases.
- Comparison of CD101 expression with established LCH markers (CD1a, S100 protein) was considered.
Main Results:
- CD101 expression was detected in 9 out of 11 LCH cases (7 positive, high in 6; low in 3).
- Two cases showed no CD101 expression.
- No significant correlation was found between CD101 expression and disease evolution, localization, or dissemination.
Conclusions:
- CD101 represents a potential new phenotypic marker for LCH diagnosis when used with other markers.
- The utility of CD101 is currently limited by the requirement for frozen sections, unlike the CD1a antibody.
Aims:
Our objective was to study the expression of a recently identified cell surface molecule, CD101 and in Langerhans cell histiocytosis (LCH) patients as CD101 has been shown to be present on dendritic cells. We wanted to determine if CD101 expression could be helpful for the diagnosis of LCH in conjunction with other markers (CD1a, S100 protein), and could be predictive of the evolution and dissemination of the disease.
Methods And Results:
The expression of CD101 was studied by immunohistochemical technique in 11 cases of Langerhans cell histiocytosis on frozen sections. The expression of CD101 was positive in nine cases, high in six cases and low in three cases. There was no expression in the other two cases. No correlation with the evolution, the localization or the dissemination of the disease could be evidenced.
Conclusions:
CD101 is a new phenotypic marker that might be useful in combination with other markers for the diagnosis of LCH. However, as the anti-CD101 antibody works only in frozen sections, its value is limited compared to anti-CD1a antibody.
